Tailored tools to improve pharmacotherapy in infants

Bibliography

• Allegaert K, Langhendries JP, van den Anker JN. Educational paper: do we need neonatal clinical pharmacologists? Eur J Pediatr 2013;172:429-35
   PubMed Web of Science ®Google Scholar
• Turner MA. Neonatal drug development. Early Hum Dev 2011;87:763-8
   PubMed Web of Science ®Google Scholar
• Stiers JL, Ward RM. Newborns, one of the last therapeutic orphans to be adopted. JAMA Pediatr 2014;168:106-8
   PubMed Web of Science ®Google Scholar
• Laughon MM, Avant D, Tripathi N, et al. Drug labeling and exposure in neonates. JAMA Pediatr 2014;168:130-6
   Web of Science ®Google Scholar
• Benjamin DK Jr, Smith PB, Murphy MD, et al. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 2006;296:1266-73
   PubMed Web of Science ®Google Scholar
• Hampson LV, Herold R, Posch M, et al. Bridging the gap: a review of dose-investigations in paediatric investigation plans. Br J Clin Pharmacol 2014. [ Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology – drug disposition, action, and therapy in infants and children. N Engl J Med 2003;349:1157-67
   PubMed Web of Science ®Google Scholar
• Smits A, Kulo A, de Hoon JN, et al. Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr Pharm Des 2012;18:3119-46
   PubMed Web of Science ®Google Scholar
• Gershanik J, Boecler B, Ensley H, et al. The gasping syndrome and benzyl alcohol poisoning. N Engl J Med 1982;307:1384-8
   PubMed Web of Science ®Google Scholar
• Saugstad OD, Aune D. Optimal oxygenation of extremely low birth weight infants: a meta-analysis and systematic review of the oxygen saturation target studies. Neonatology 2014;105:55-63
   PubMed Web of Science ®Google Scholar
• Kemper EM, Merkus M, Wierenga PC, et al. Towards evidence-based pharmacotherapy in children. Paediatr Anaesth 2011;21:183-9
   PubMed Web of Science ®Google Scholar
• De Cock RF, Piana C, Krekels EH, et al. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol 2011;67(Suppl 1):5-16
   PubMedGoogle Scholar
• Laughon MM, Benjamin DK Jr, Capparelli EV, et al. Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 2011;4:643-52
   PubMedGoogle Scholar
• Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008;47:231-43
   PubMed Web of Science ®Google Scholar
• Krekels EH, Tibboel D, de Wildt SN, et al. Evidence-based morphine dosing for postoperative neonates and infants. Clin Pharmacokinet 2014;53(6):553-63
   PubMed Web of Science ®Google Scholar
• Krekels EH, Neely M, Panoilia E, et al. From pediatric covariate model to semiphysiological function for maturation: part I-extrapolation of a covariate model from morphine to zidovudine. CPT Pharmacometrics Syst Pharmacol 2012;1:e9
   PubMedGoogle Scholar
• de Cock RF, Allegaert K, Sherwin CM, et al. A neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates. Pharm Res 2014;31:754-67
   PubMed Web of Science ®Google Scholar
• Abduljalil K, Jamei M, Rostami-Hodjegan A, et al. Changes in individual drug-independent system parameters during virtual paediatric pharmacokinetic trials: introducing time-varying physiology into a paediatric PBPK model. AAPS J 2014;16(3):568-76
   PubMed Web of Science ®Google Scholar
• Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev 2008;6(3):CD001340
   Google Scholar
• Ahsman MJ, Hanekamp M, Wildschut ED, et al. Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates. Clin Pharmacokinet 2010;49:407-19
   PubMed Web of Science ®Google Scholar
• Ahsman MJ, Wildschut ED, Tibboel D, et al. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother 2010;54:1734-41
   PubMed Web of Science ®Google Scholar
• van der Vorst MM, den Hartigh J, Wildschut E, et al. An exploratory study with an adaptive continuous intravenous furosemide regimen in neonates treated with extracorporeal membrane oxygenation. Crit Care 2007;11:R111
   PubMed Web of Science ®Google Scholar
• Watt K, Li JS, Benjamin DK Jr, et al. Pediatric cardiovascular drug dosing in critically ill children and extracorporeal membrane oxygenation. J Cardiovasc Pharmacol 2011;58:126-32
   PubMed Web of Science ®Google Scholar
• Wildschut ED, Ahsman MJ, Allegaert K, et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 2010;36:2109-16
   PubMed Web of Science ®Google Scholar
• Edwards AD, Brocklehurst P, Gunn AJ, et al. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ 2010;340:c363
   PubMed Web of Science ®Google Scholar
• Van den Broek MP, Groenendaal F, Toet MC, et al. Pharmacokinetics and clinical efficacy of phenobarbital in asphyxiated newborns treated with hypothermia: a thermopharmacological approach. Clin Pharmacokinet 2012;51:671-9
   PubMed Web of Science ®Google Scholar
• Liu X, Borooah M, Stone J, et al. Serum gentamicin concentrations in encephalopathic infants are not affected by therapeutic hypothermia. Pediatrics 2009;124:310-15
   PubMed Web of Science ®Google Scholar
• Wildschut ED, de Wildt SN, Mathot RA, et al. Effect of hypothermia and extracorporeal life support on drug disposition in neonates. Semin Fetal Neonatal Med 2013;18:23-7
   PubMed Web of Science ®Google Scholar
• Wildschut ED, van Saet A, Pokorna P, et al. The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children. Pediatr Clin North Am 2012;59:1183-204
   PubMed Web of Science ®Google Scholar
• Stojančević M, Bojić G, Salami HA, et al. The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr Issues Mol Biol 2013;16:55-68
   PubMed Web of Science ®Google Scholar
• Matuskova Z, Anzenbacherova E, Vecera R, et al. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PLoS One 2014;9:e87150
   PubMed Web of Science ®Google Scholar
• Sherman PM, Cabana M, Gibson GR, et al. Potential roles and clinical utility of prebiotics in newborns, infants, and children: proceedings from a global prebiotic summit meeting, New York City, June 27-28, 2008. J Pediatr 2009;155:S61-70
   PubMed Web of Science ®Google Scholar
• Blake MJ, Abdel-Rahman SM, Pearce RE, et al. Effect of diet on the development of drug metabolism by cytochrome P-450 enzymes in healthy infants. Pediatr Res 2006;60:717-23
   PubMed Web of Science ®Google Scholar
• Blake MJ, Gaedigk A, Pearce RE, et al. Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 2007;81:510-16
   PubMed Web of Science ®Google Scholar
• del Mar Fernandez de Gatta M, Martin-Suarez A, Lanao JM. Approaches for dosage individualisation in critically ill patients. Expert Opin Drug Metab Toxicol 2013;9:1481-93
   PubMed Web of Science ®Google Scholar
• Ince I, de Wildt SN, Peeters MY, et al. Critical illness is a major determinant of midazolam clearance in children aged 1 month to 17 years. Ther Drug Monit 2012;34:381-9
   PubMed Web of Science ®Google Scholar
• Wang C, Allegaert K, Peeters MY, et al. The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults. Br J Clin Pharmacol 2014;77:149-59
   PubMed Web of Science ®Google Scholar
• Grootaert V, Willems L, Debaveye Y, et al. Augmented renal clearance in the critically ill: how to assess kidney function. Ann Pharmacother 2012;46:952-9
   PubMed Web of Science ®Google Scholar
• De Cock RF, Allegaert K, Schreuder MF, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 2012;51:105-17
   PubMed Web of Science ®Google Scholar
• Allegaert K, Cossey V, Langhendries JP, et al. Effects of co-administration of ibuprofen-lysine on the pharmacokinetics of amikacin in preterm infants during the first days of life. Biol Neonate 2004;86:207-11
   PubMedGoogle Scholar
• George I, Mekahli D, Rayyan M, et al. Postnatal trends in creatininemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatr Nephrol 2011;26:1843-9
   PubMed Web of Science ®Google Scholar
• Allegaert K, Kuppens K, Mekahli D, et al. Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method. J Matern Fetal Neonatal Med 2012;25:1678-81
   PubMed Web of Science ®Google Scholar
• Martínková J, Pokorná P, Záhora J, et al. Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: an open-label, prospective study. Clin Ther 2010;32:2400-14
   PubMed Web of Science ®Google Scholar
• Leeder JS, Kearns GL, Spielberg SP, et al. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science. J Clin Pharmacol 2010;50:1377-87
   PubMed Web of Science ®Google Scholar
• Leeder JS, Kearns GL. Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target. Clin Pharmacol Ther 2012;92:434-6
   PubMed Web of Science ®Google Scholar
• Allegaert K, van den Anker J, de Hoon JN, et al. Covariates of tramadol disposition in the first months of life. Br J Anaesth 2008;100:525-32
   PubMed Web of Science ®Google Scholar
• Zhu R, Kiser JJ, Seifart HI, et al. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J Clin Pharmacol 2012;52:511-19
   PubMed Web of Science ®Google Scholar
• Wachman EM, Hayes MJ, Brown MS, et al. Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA 2013;309:1821-7
   PubMed Web of Science ®Google Scholar
• Oberlander TF, Bonaguro RJ, Misri S, et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2008;13:65-73
   PubMed Web of Science ®Google Scholar
• Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 2006;368:704
   PubMed Web of Science ®Google Scholar
• Kelly LE, Chaudhry SA, Rieder MJ, et al. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. PLoS ONE 2013;8:e70073
   Google Scholar
• Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001;285:2114-20
   PubMed Web of Science ®Google Scholar
• Chedoe I, Molendijk HA, Dittrich ST, et al. Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature. Drug Saf 2007;30:503-13
   PubMed Web of Science ®Google Scholar
• Morriss FH Jr, Abramowitz PW, Nelson SP, et al. Effectiveness of a barcode medication administration system in reducing preventable adverse drug events in a neonatal intensive care unit: a prospective cohort study. J Pediatr 2009;154:363-8
   PubMed Web of Science ®Google Scholar
• Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000;83:F177-81
   PubMed Web of Science ®Google Scholar
• Lazou K, Farini M, Koutkias V, et al. Adverse drug event prevention in neonatal care: a rule-based approach. Stud Health Technol Inform 2013;186:170-4
   PubMedGoogle Scholar
• Victor S, Dickinson H, Turner MA. Plasma aminotransferase concentrations in preterm infants. Arch Dis Child Fetal Neonatal Ed 2011;96:F144-5
   PubMedGoogle Scholar
• Teune MJ, van Wassenaer AG, Malin GL, et al. Long-term child follow-up after large obstetric randomised controlled trials for the evaluation of perinatal interventions: a systematic review of the literature. BJOG 2013;120:15-22
   PubMed Web of Science ®Google Scholar
• Du W, Lehr VT, Leih-Lai M, et al. An algorithm to detect adverse drug reactions in the neonatal intensive care unit. J Clin Pharmacol 2013;53:87-95
   PubMed Web of Science ®Google Scholar
• Jacqz-Aigrain E. Drug policy in Europe Research and funding in neonates: current challenges, future perspectives, new opportunities. Early Hum Dev 2011;87(Suppl 1):27-30
   PubMed Web of Science ®Google Scholar
• de Haan TR, Bijleveld YA, van der Lee JH, et al. Pharmacokinetics and pharmacodynamics of medication in asphyxiated newborns during controlled hypothermia. The PharmaCool multicenter study. BMC Pediatr 2012;12:45
   PubMed Web of Science ®Google Scholar
• de Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 2011;7:935-48
   PubMed Web of Science ®Google Scholar
• Hines RN. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm 2013;452:3-7
   PubMed Web of Science ®Google Scholar
• Salem F, Johnson TN, Barter ZE, et al. Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol 2013;53:857-65
   PubMed Web of Science ®Google Scholar
• Himebauch AS, Zuppa A. Methods for pharmacokinetic analysis in young children. Expert Opin Drug Metab Toxicol 2014;10:497-509
   PubMed Web of Science ®Google Scholar
• De Cock RF, Smits A, Allegaert K, et al. Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. J Antimicrob Chemother 2014;69:1330-8
   PubMed Web of Science ®Google Scholar
• Allegaert K, Smits A, van den Anker JN. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician’s request for a more integrated approach. J Biomed Biotechol 2012;2012:103763
   PubMedGoogle Scholar
• Bai JP, Barrett JS, Burckart GJ, et al. Strategic biomarkers for drug development in treating rare diseases and diseases in neonates and infants. AAPS J 2013;15:447-54
   PubMed Web of Science ®Google Scholar
• Zhao W, Kaguelidou F, Biran V, et al. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br J Clin Pharmacol 2013;75:1068-80
   PubMed Web of Science ®Google Scholar
• Reed MD. Reversing the myths obstructing the determination of optimal age- and disease-based drug dosing in pediatrics. J Pediatr Pharmacol Ther 2011;16:4-13
   Google Scholar